Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient. Issue 1 (January 2020)

• Record Type: Journal Article
• Authors: Farhat, Fadi; Tarabaih, Mohammad; Kanj, Ali; Aoun, Majeda; Kattan, Joseph; Assi, Tarek; Awada, Ahmad
• Is Part Of: Anti-cancer drugs. Volume 31:Issue 1(2020)
• Publication Date: 2020-01
• Subjects: breast cancer -- CDK4/6 -- hormone-positive -- liver toxicity -- palbociclib -- ribociclib; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000845
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer. Liver toxicity is common with these agents, but no data are reported on the sequential use of these CDK4/6 inhibitors in case of confirmed efficacy and intolerable toxicity. In this article, we report the successful use of Palbociclib in a metastatic positive hormone-receptors breast cancer patient after initial response to Ribociclib, which was interrupted for grade 4 liver toxicity.